These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 20432857

  • 21. A rapid and simple assay to determine pegylated erythropoietin in human serum.
    Van Maerken T, Dhondt A, Delanghe JR.
    J Appl Physiol (1985); 2010 Apr; 108(4):800-3. PubMed ID: 20093664
    [Abstract] [Full Text] [Related]

  • 22. Darbepoetin alfa: new preparation. Just a me-too: no advantage in anaemia of chronic renal failure.
    Prescrire Int; 2003 Feb; 12(63):14-6. PubMed ID: 12602375
    [Abstract] [Full Text] [Related]

  • 23. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease.
    Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B.
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1211-5. PubMed ID: 17699350
    [Abstract] [Full Text] [Related]

  • 24. Once weekly treatment with epoetin-beta.
    Locatelli F.
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi26-30. PubMed ID: 15958823
    [Abstract] [Full Text] [Related]

  • 25. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M, Uday K, Henriquez M, Blum S, Dave M.
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract] [Full Text] [Related]

  • 26. The benefits of IV iron therapy in treating anemia in patients with renal disease and comorbid cardiovascular disease.
    Singh AK, Hertello P.
    Nephrol Nurs J; 2005 Jul; 32(2):199-206; quiz 207-8. PubMed ID: 15889804
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration.
    Fishbane S, Pannier A, Liogier X, Jordan P, Dougherty FC, Reigner B.
    J Clin Pharmacol; 2007 Nov; 47(11):1390-7. PubMed ID: 17962427
    [Abstract] [Full Text] [Related]

  • 30. [The role of erythropoietin].
    Godin M.
    Soins; 2004 Sep; (688 Suppl):5. PubMed ID: 15526820
    [No Abstract] [Full Text] [Related]

  • 31. Management of the anaemia of chronic renal failure with recombinant erythropoietin.
    Adamson JW, Eschbach JW.
    Q J Med; 1989 Dec; 73(272):1093-101. PubMed ID: 2694210
    [No Abstract] [Full Text] [Related]

  • 32. Drug usage evaluation of epoetin in chronic renal failure.
    Mason NA, Iacobellis DP.
    Hosp Formul; 1992 Sep; 27(9):928-32, 937-8. PubMed ID: 10121421
    [Abstract] [Full Text] [Related]

  • 33. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks.
    Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, Villa G, Rosansky S, Adamis H, Beyer U, RUBRA Study Investigators.
    Am J Nephrol; 2008 Sep; 28(2):280-9. PubMed ID: 18004064
    [Abstract] [Full Text] [Related]

  • 34. [CERA: Continuous Erythropoietin Receptor Activator for anemia in CKD patients].
    Cozzolino M.
    G Ital Nefrol; 2009 Sep; 26(1):8. PubMed ID: 19255955
    [No Abstract] [Full Text] [Related]

  • 35. Treatment of the anaemia of chronic renal failure with recombinant human erythropoietin.
    Winearls CG.
    Drugs; 1989 Sep; 38(3):342-5. PubMed ID: 2806134
    [No Abstract] [Full Text] [Related]

  • 36. Methoxypolyethylene glycol-epoetin beta for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L, Cavalli A, Locatelli F.
    Drugs Today (Barc); 2008 Aug; 44(8):577-84. PubMed ID: 18846269
    [Abstract] [Full Text] [Related]

  • 37. Is it time to reconsider subcutaneous administration of epoetin?
    Patel TV, Robinson K, Singh AK.
    Nephrol News Issues; 2007 Oct; 21(11):57, 59, 63-4 passim. PubMed ID: 17970510
    [Abstract] [Full Text] [Related]

  • 38. Continuous erythropoietin receptor activator (Mircera) for renal anemia.
    McGahan L.
    Issues Emerg Health Technol; 2008 Feb; (113):1-6. PubMed ID: 18354858
    [Abstract] [Full Text] [Related]

  • 39. [The pharmacokinetics of recombinant human erythropoietin].
    Siniukhin VN, Stetsiuk EA, Lovchinskiĭ EV, Lebedev SV, Iarmolinskiĭ IS, Liakhov VV.
    Ter Arkh; 1994 Feb; 66(8):60-2. PubMed ID: 7985158
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.